|Greater London, Sutton
|£47,500 to £59,360 Staff Scientist/Senior Staff Scientist
|7th December 2023
|15th January 2024
Under the leadership of Olivia Rossanese, we are seeking to appoint a talented, experienced drug discovery biologist to join the Target Evaluation & Molecular Therapeutics (TEMT) team as a Staff Scientist / Senior Staff Scientist.
The successful candidate will have the opportunity to contribute scientific excellence, biology expertise, and strategic thinking to drug discovery projects in the lab and the Centre for Cancer Drug Discovery (CCDD).
Commitment to making a difference to patients through translational and drug discovery research is fundamental to this position. The role requires application of molecular pharmacology and cancer biology approaches to support hypothesis-driven target validation decisions, implement functional and mechanistic assays to support progression of potential small molecule therapeutics, and develop and test hypotheses regarding patient selection strategies. Enthusiasm for working in a collaborative interdisciplinary environment is essential as the post holder will work within larger project teams towards the goal of developing a better understanding of the causes, molecular mechanisms, and treatment of cancer. A good research track record with proven ability to publish papers is essential.
The Division of Cancer Therapeutics has an unrivalled track record at discovering novel cancer treatments for the personalised treatment of cancer. Within the Division, the Centre for Cancer Drug Discovery (CCDD) is a multidisciplinary 'bench to bedside' centre, comprising 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. We are one of the largest academic cancer drug discovery groups in the world and, together with our collaborators, have discovered 21 preclinical development candidates, 13 of which have been progressed to clinical evaluation, many with our partners in the ICR/Royal Marsden Drug Development Unit. Our drug abiraterone (Zytiga) has been approved in the US, Canada and Europe for late-stage prostate cancer.
The CCDD’s mission is to develop personalised medicines by translating information from the cancer genome and cancer biology into drugs for patient benefit. We implement innovative drug discovery technologies, discover novel mechanism-based drugs, and develop these as rapidly as possible from the laboratory through to hypothesis-testing early clinical trials. We publish our work extensively and have a large network of collaborations with academia, biotechnology companies, and the pharmaceutical industry. Our teams are dedicated to the discovery of small molecule drug candidates, and to the development of high quality chemical probes to enable new cancer biology research. The Division of Cancer Therapeutics is based in state-of-the art laboratories in the new £75m Centre for Cancer Drug Discovery building, opened in 2020 on the ICR Sutton campus.
We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Olivia Rossanese via Email on email@example.com.
We look forward to receiving applications from all candidates, wherever in the world they are currently based. We will select those who display the potential to become, or to support, the world leading cancer researchers of the future based on their application and performance at interview. However, we particularly welcome British applicants from black and ethnic minority backgrounds, as they are under-represented within the ICR and nationwide in STEM roles.
Type / Role: